Large Molecule Bioanalysis done differently

To help you achieve more.

We are a bioanalytical lab that has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.

Services Delivered Scientist to Scientist

Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.

biomarkers

Biomarkers

immunogenicity

Immunogenicity

pharmacokinetics

Pharmacokinetics (PK)

cell-based-assays

Cell-Based Assays

Solutions Enabled by World-Leading Expertise

Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.

biosimilars

Biosimilars

gene-therapy

Gene Therapy

antibody-drug-conjugates

Antibody Drug Conjugates (ADCs)

immuno-oncology

Immuno-oncology

platform comparison guide

webinar title
NOW ACCESSIBLE ON-DEMAND

Clinical Relevance of (Unwanted Drug-Induced) Immune Responses

Webinar Co-Hosted with Bioanalysis Zone

Methods for the detection of drug-induced antibodies have become much more sensitive, but the question remains to be answered: are antibodies at this low concentration level clinically relevant? BioAgilytix Europe’s Dr. Arno Kromminga addresses this subject and more.

Download Recording

The Bioagilytix Perspective

Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.

resource center

Visit Resource Center

usa europe labs

Advanced bioanalytical lab facilities to support all phases of large molecule global studies.

    LinkedIn Company Updates

  • Today Agoview on linkedin

    BioAgilytix

    Our team will be attending a number of industry events throughout 2019 to take part in discussions about innovative bioanalysis and interface with industry thought leaders. See where we’ll be and how you can meet with us: https://lnkd.in/e8XsJnN

  • 3 Days Agoview on linkedin

    BioAgilytix

    A comprehensive genome-wide association study of colorectal cancer risk produced 40 new genetic variants and validated 55 previously identified variants, all of which signal an increased risk of colon cancer. Read more via ScienceDaily: https://lnkd.in/efrsQRh

  • 3 Days Agoview on linkedin

    BioAgilytix

    BioAgilytix scientists have deep experience supporting complex biosimilar studies, and have contributed their knowledge help shape a number of biosimilar publications on the topic: https://lnkd.in/gawQUTG

global map

Advancing Bioanalytical Excellence Internationally

Choose a Location to learn more about the premier bioanalytical services and solutions available at each of our advanced laboratories in the USA and Europe.